Case Study On The Impact Of Medical Policy On The Performance Of Contract Research Organizations

Medicine has become one of the national key industries.Since July 2015,the State Council,the CDFA,and the CDE has published A new policy on drug review on the supply side intensively,which has been reflected in the business thinking and performance of pharmaceutical companies in recent years.Based on the above background,this paper seeks to explore the impact of the pharmaceutical industry's core policies on the performance of contractual research organizations.In this paper,through statistical industry policies and surveys of relevant enterprises,we analyze how the medical policies discussed in this paper have changed the industry,and then cut into the regular announcements and annual reports of public disclosure of listed companies,and continuously follow up the follow-up quarterly reports,interim reports and annual reports to determine the correlation between policies and financial data.Sex.This paper mainly explains the guidance of the policy to the industry through the formulation and implementation of the strategy of listed companies,and evaluates the prosperity of the industry under the new policy by analyzing the financial reports of listed companies.This study is divided into four parts.Chapter 1 and 2 complete the background information collation.Chapter 3 combs the relevant policies of contract research organizations.Chapter 4 analyses how policies transmit to enterprise performance.Chapter 5 analyses the performance of Mingkang and Tiger Pharmaceuticals after the implementation of the new policies.Through research,in 2015,in view of the pain points in China's pharmaceutical industry,such as slow approval of new drug listing and discontinuation of innovative varieties,the regulatory authorities pushed for drug registration reform,and supporting policies were introduced successively.Both domestic innovative drugs and high-end generic drugs have ushered in the golden development period.Domestic a contract research organization at the head position in the industry,such as wuxi,tiger medicine in a more efficient policy environment,the performance good,denotative development is more positive,on the one hand speed expansion in the domestic production capacity,on the other hand,to strengthen the international status,set up more than international center in the laboratory and involved in the development of innovative drugs.This paper argues that the new policy has improved the business climate in the field of contract research organization and has been reflected in the recent annual financial statements of related companies.